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Abstract
Background: Our previous study indicated that a common variant (rs430397 G.A) in the intron 5 of glucose-regulated
protein 78 (GRP78) gene was associated with risk and prognosis of primary hepatocellular carcinoma (HCC), including HBV-
and cirrhosis-related HCC. rs430397 polymorphism may be a contributing factor or biomarker of HBV infection or HBV-
related cirrhosis.
Methodology/Principal Findings: 539 non-HBV-infected individuals, 205 self-limited infection and 496 persistent HBV
infection were recruited between January 2001 and April 2005 from the hospitals in Southern China. Genomic DNA was
genotyped for rs430397. The associations between the variation and susceptibility to liver cirrhosis (LC) in persistent HBV
infection were examined. We observed that individuals carrying allele rs430397A were more likely to become HBV-related
LC. When persistently infected patients were divided into four subgroups, patients with phase IV had an increased allele A
and genotype AG compared with phase I and/or phase III. Decreased serum albumin and prolonged plasma prothrombin
time (PT) were showed in LC patients carrying genotype AA. Furthermore, rs430397 genotype had an increased
susceptibility to LC with dose-dependent manners (P-trend=0.005), and the genotype did constitute a risk factor for the
development of advanced LC (Child–Pugh classification C and B, P-trend=0.021).
Conclusions/Significance: rs430397 polymorphism may be a contributing factor to LC in persistent HBV carriers.
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Introduction
Hepatitis B, also called serum hepatitis, is a global health
problem that affects more than 400 million of the world’s
population [1]. It is estimated that the prevalence of chronic
hepatitis B virus (HBV) infection in China is approximately 10–
20% of the population, where it represents the leading cause of
cirrhosis and hepatocellular carcinoma [2]. Although HBV does
not directly cause hepatic cytopathic effects, 15% to 40% HBV
carriers will develop serious sequelae during their lifetime [1].
However, the mechanisms underlying the chronic HBV infection
and its progression to different outcomes remain largely unsolved.
Increasing evidences indicate that genetic factors might influence
the natural history of chronic liver diseases [3,4,5,6].
Like other viruses, HBV induce endoplasmic reticulum (ER)
stress, which interrupts protein folding causing accumulation of
unfolded or misfolded proteins in ER. To alleviate the stress
placed on ER, these proteins must be refolded or degraded by
activating a specific cellular response known as ER stress response
or unfolded protein response (UPR) [7]. Glucose-regulated
protein 78 (GRP78), which is a member of the HSP70 family
of proteins and is found in the lumen of the ER is known to be a
major cellular target of the UPR [8]. It not only binds to unfolded
proteins but also regulates the activation of ER stress transducers
such as IRE1, PERK, and ATF6 [9]. Based on these
backgrounds, the transcriptional activation of the GRP78 is used
extensively as a biological marker for onset of the UPR, as well as
an unique model for deciphering the mechanisms whereby ER
stress upregulates nuclear gene expression. With respect to liver
disease, GRP78 may play an important role in HBV morpho-
genesis by regulating proper folding of the L protein and/or
assembly of the envelope proteins [10]. GRP78 has also been
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carcinoma (HCC) [11].
HBV invasion and other physiopathologic changes cause large
amount of unfolding or false-folding protein accumulation in the
endoplasmic reticulum (ER), which in turn induces expression of
GRP78 [12]. Our previous studies revealed that 287 T.A (a new
mutation from the estimated translation start site of GRP78 gene),
the promoter and 39 untranslated region (UTR) were not associated
with HBV infection [13,14]. Our recent studies showed that the 39
UTR variants of GRP78 were also not associated with risk and
prognosis of HCC [15,16]. But a common variant (rs430397 G.A)
in the GRP78 was found to be associated with risk and prognosis of
primary HCC, including HBV- and cirrhosis-related HCC [17].
rs430397 is located in the intron 5 of GRP78 and adjoin the 39-end
of the intron. Intronic mutation may be involved in DNA damage,
mitogenic response and stress [18,19]. Therefore, we hypothesized
that rs430397 variant may also be a contributing factor to HBV
infection and/or HBV-related cirrhosis. Accordingly, a large case-
control study was conducted to further investigate this hypothesis
among a Han Chinese population in Southern China.
Materials and Methods
Subjects and study design
The study protocol was approved by the Ethics Committee of
Guangdong Medical College and adhered to the tenets of the
Declaration of Helsinki. Additionally, written informed consent
was obtained from each participant or each participant’s guardian.
A total of 701 HBV-infected patients from southern China, a
high-risk region of HBV infection, were recruited between January
2001 and April 2005. Of the 701 HBV-infected patients, 205 had
self-limited infections with antibody to HBsAg-positive and
antibody to HBcAg-positive, and 496 had persistent infections
with HBsAg of the immunoglobulin G type in the serum for more
than 36 months. All carriers were measured with liver function
tests, serum immunologic marker screening, and liver ultrasonog-
raphy. Some were screened by computed tomography (CT) and/
or magnetic resonance imaging (MRI). Liver biopsies were
performed in 103 patients, and the diagnosis of cirrhosis was
made based on liver histology [20]. In patients without biopsy
specimens, the diagnosis of cirrhosis was based on the presence of
clinical manifestations of portal hypertension, ascites, biochemical
evidences and obvious morphologic change of the liver detected by
hepatic imaging. All carriers had no serologic evidence for
coinfection with hepatitis C virus (HCV), hepatitis D virus
(HDV), and human immunodeficiency virus (HIV). Patients with
other types of liver diseases, such as autoimmune liver diseases,
alcoholic liver diseases, or metabolic liver diseases, were also
excluded. No evidence of tumors was found in patients with HBV
after undergoing diagnostic procedures.
Patients with persistent infection, including 89 chronic HBV
carriers (CHC) which based on sustained normalization of the
serum alanine aminotransferase (ALT) levels together with
seropositivity for HBeAg and high HBV-DNA levels throughout
the study; 101 inactive hepatitis B surface antigen carrier (IHC)
which has not shown significant, ongoing necroinflammatory
disease; 108 chronic hepatitis B (CHB) which based on clinical
symptoms, elevated serum aminotransferase levels, and/or
abnormalities of other liver functions; and 198 liver cirrhosis
(LC) which showed serum HBsAg, abnormal liver function profiles
and portal hypertension, according to the guidelines of the
American Association for the Study of Liver Diseases [21] and
others [22,23]. Child-Pugh score (CPS) was calculated in LC
patients [24] and the LC patients were further divided into calss A
(43), class B (87) and class C (68). According to the state of immune
response, patients with persistent HBV infection can be classified
as: phase I, immunotolerance phase, a chronic HBV carrier; phase
II, immunoresponse phase, with HBeAg-positive chronic hepatitis
or LC; phase III, an inactive HBsAg carrier and phase IV, with
HBeAg-negative chronic hepatitis or LC [25,26].
During the same time, 539 healthy adults, frequcncy-matched
by gender and age (66 years) group, from the above hospitals and
other hospitals in Guangzhou region after physical checkup were
enrolled as the control series. All the healthy controls were tested
to exclude HBV, HCV, HIV infection and other conspicuous
diseases. The main features of the subjects included are
summarized in Table 1.
Resequencing and TaqMan genotyping
Resequencing and TaqMan genotyping were performed accord-
ing to the methods described previously [17]. Briefly, Genomic
DNA was extracted from peripheral blood leukocytes using
QIAGEN QIAamp DNA Mini Blood Kit (Hilden, Germany)
according to the manufacture’s instructions. PCR was performed in
a5 0 ml reaction systems containing forward primer (AGTAT-
TCTCGGTTGGCTGTTATG) and reverse primer (AGTTGCT-
GAATCTTTGGA). Resequencing was performed directly withthe
reverse primer, Taq polymerase, ABI PRISMH BigDye
TM termina-
tors on an ABI 37306l DNA Analyzer (Applied Biosystems, Inc.,
Foster City, CA, USA). TaqMan high-throughput allelic discrimi-
nation assay was performed with a commercial kit (Applied
Biosystems). The PCRs were run on the TaqMan Genotyping
Master Mix without UNG (Applied Biosystems), with a PCR primer
concentrationof500 nMandaTaqManMGB-probeconcentration
of 200 nM. The reactions were carried out in a 96-well format in a
total reactionvolumeof 20 ml using50 ngofthe genomicDNA.The
plates were then placed in a thermal cycler (ABI 7500 Fast System,
Applied Biosystems, FosterCity, CA) and heated to 95uC for 10 min
followed by 40 cycles of 92uC for 15 s and 60uCf o r1m i n .
Statistical analysis
Mann–Whitney U-test was used to test the difference among the
age groups. Chi-square test was used to determine whether there
was a significant difference between groups. Hardy-Weinberg
equilibrium (HWE) of genotype distribution among cases and
controls was examined using the Pearson Chi-square test by Plink
program [27]. Odds ratios (ORs) with 95% confidence intervals
(95%CI)werecomputed bylogisticregressionto testtheassociation
of certain genotype with HBV infection and progression. We
compared the minor allele genotypes to the most common genotype
as a reference group. All statistical tests were 2-sided and P values
less than 0.05 were considered statistically significant.
Results
rs430397 variant in individuals with non-HBV-infection,
self-limited infection and persistent HBV infection
The genotype distributions of rs430397 G.A in these groups
were in HWE. Meanwhile, a power analysis of the study
population showed that our sample size was large enough to
detect a possible association (date not shown). The genotyping
results for individuals with non-HBV infection, self-limited
infection and persistent HBV infection are shown in Table 2.
Compared with individuals with non-HBV-infection or self-
limited-infection, patients with LC were significantly more likely
to carry allele A (P=0.004 or P=0.023). For the genotypes, the
proportion of the AA genotype (6.57%) in patients with LC was
different from that in non-HBV-infected individuals (3.15%;
rs430397 Polymorphism Predicts Cirrhosis
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(60.10%) was significantly lower in LC patients compared to
those without HBV infection (69.76%; P=0.013). Although no
statistical difference was found in allelic or genotypic frequencies
among CHC, IHC, CHB and LC groups, a greater frequency of
allele A (23.23%) or genotype AA (6.57%) in LC patients was
found in comparison with the other groups. According to the
Table 2, no statistical difference was found between the total
persistent infection patients and the non-HBV-infected individuals
or the self-limited infection patients (P.0.05, respectively).
Relationship between the genotype distribution of
rs430397 G.A and the status of HBeAg and immune
response
Among 496 patients with persistent HBV infection, 193 carried
HBeAg in the serum. The genotype distribution of rs430397 was
not significantly different between patients with and without
HBeAg. However, compared with the allele A in phase I group
(12.92%) and phase III group (14.36%), phase IV group had a
significantly higher frequency of allele A (22.77%; P=0.006 and
P=0.015). Though the distribution of genotype AA between the
groups was similar, the genotype GG was significantly lower in
phase IV group (60.40%) than those in phase I group (77.53%,
P=0.005) and those in phase III group (73.27%, P=0.027). In
addition, compared with phase I group, phase IV group had a
significantly higher frequency of heterozygote AG (33.66% versus
19.10%, P=0.008) (Table 3).
Relationship between rs430397 genotype distribution
and liver function profiles in patients with LC
All variables of interest, including liver function test results were
listed in Table 4. The genotype distribution of rs430397 had no
influence on common liver function, including total bilirubin (T-
Bil), ALT, aspartate aminotransferase (AST) and c-glutamyltrans-
ferase (GGT). But compared with the LC patients carrying GG
genotype, those patients carrying AA genotype had a significantly
lower ALB (23.666.9 g/L versus 27.166.7 g/L, P=0.029) and a
significantly higher PT (29.066.7 s versus 22.766.5 s, P=0.016).
Risk factors for the development of advanced cirrhosis in
HBV patients
To assess the possible association between the polymorphism
and cirrhosis in HBV infection, the cases were divided into two
groups based on the absence or presence of cirrhosis. Significant
Table 1. Clinical and laboratory features of the subjects included in the study.
Characteristics
Non-HBV-infected
Individuals
n=539
Self-limited
Infection
n=205 Persistent infection
Total
n=496
CHC
n=89
IHC
n=101
CHB
n=108
LC
n=198
Age (years)
Mean 6 SD 43.069.7 38.169.0 41.9613.5 34.869.5 37.9610.3 42.5610.6 43.9611.8
Gender (%)
Female 232 (43.04) 61 (29.76) 193 (38.91) 38 (42.70) 44 (43.56) 46 (42.59) 65 (32.83)
Male 307 (56.96) 144 (70.24) 303 (61.09) 51 (57.30) 57 (56.44) 62 (57.41) 133 (67.17)
Liver function test (mean6SD)
T-Bil (mmol/L) 4.863.0 17.468.5 117.3689.2 31.5613.9 35.6615.0 118.9676.1 158.1694.9
ALB (g/L) 44.665.9 34.667.0 31.266.7 32.166.1 33.464.9 30.765.8 25.766.5
ALT (IU/L) 26.7611.4 27.169.8 161.1695.5 30.7610.4 32.4615.9 263.86180.4 160.96118.1
AST (IU/L) 16.4611.0 33.0613.6 128.86107.4 27.7611.9 29.8610.6 160.56122.5 136.66101.8
GGT (IU/L) 14.5610.8 28.2611.6 73.7638.1 31.7610.2 29.4614.8 142.4688.3 85.1650.5
PT (seconds) unknown unknown unknown unknown unknown unknown 24.266.6
HBV serum tests (%)
HBsAg (+) 0 0 496 (100) 89 (100) 101 (100) 108 (100) 198 (100)
HBeAg (+) 0 0 193 (38.91) 89 (100) 0 47 (43.52) 57 (28.79)
HBV-DNA (lg copies/mL) 0 0 4.8862.31 4.9661.15 3.5560.91 4.6262.29 5.9461.80
Method of diagnosis (%)
Histology 103 (20.77) 12 (13.48) 8 (7.92) 22 (20.37) 61 (30.81)
CT or MRI 80 (16.13) 3 (3.37) 5 (4.95) 14 (12.96) 58 (29.29)
Ultrasonic 496 (100) 89 (100) 101 (100) 108 (100) 198 (100)
Child-Pugh score (%)
Class A 43 (21.72)
Class B 87 (43.94)
Class C 68 (34.34)
ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHB, chronic hepatitis B; CHC, chronic hepatitis B virus carrier; CT, computed
tomography; GGT, c-glutamyltransferase; HBV, hepatitis B virus; IHC, inactive hepatitis B surface antigen carrier; LC, liver cirrhosis; MRI, Magnetic resonance imaging; PT,
prothrombin time; SD, standard deviation;. T-Bil, total bilirubin.
doi:10.1371/journal.pone.0021997.t001
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(P=0.011 or P=0.014) and increased risk of HBV-related
cirrhosis was found. The risk of cirrhosis increased with a dose-
dependent manner as rs430397A allele increased (P-trend=0.005;
Table 5).
When the LC patients were divided using CPS, the distributions
of age, gender and positive HBeAg did not differ significantly
between the patients with advanced LC (CPS classes C and B) and
those with mild LC (CPS class A; P.0.05 in each parameter),
whilst the distributions of rs430397 alleles A and genotype AA
were noted to be significantly different between these two groups
(P=0.010 or P=0.032). The results of multivariable logistic
regression analysis demonstrated that the rs430397 genotype did
constitute a risk factor for the development of advanced LC (P-
trend=0.021; Table 6).
Discussion
Host genetic factors are widely viewed as the common basis of
the different outcomes of HBV infection [28,29,30]. Our current
study demonstrated a statistical relationship of rs430397 polymor-
phism of GRP78 gene with HBV-related LC. Compared with
individuals with non-HBV-infection or self-limited-infection,
patients with LC were significantly more likely to carry allele A.
For the genotype, the proportion of the AA genotype in patients
with LC was higher than that in non-HBV-infected individuals.
This finding indicated that patients carry allele A or genotype AA
have an increased risk of LC compared with those carry allele G or
genotype GG. In addition, logistic regression analysis showed that
rs430397 genotype had an increased susceptibility to LC with a
dose-dependent manner.
The functional severity of LC is usually described by CPS [31].
According to CPS, patients of LC in the present study were
classified into calss A (mild), class B (moderate) and class C (severe).
Notably, allele A and genotype AA constitute risk factors for the
progression of advanced LC. It may suggest that rs430397 may
also be a determinant for the degree of LC severity.
Although the genotype distribution of rs430397 was not
significantly different between patients with and without HBeAg,
when taking immune response phases of infection into account,
the frequencies of allele A and heterozygote AG were significantly
higher in phase IV group (HBeAg negative CHB or LC) compared
with phase I group (chronic HBV carrier) and phase III group
(inactive hepatitis B surface antigen carrier). This result does not
reject the effect of rs430397 G.A on HBeAg maturation or
seroconversion. Rather, HBV infected patients with allele A and
Table 2. Genotype distribution of rs430397 G.A in the fifth intron of the GRP78 gene in HBV-infected individuals with different
clinical outcomes.
Variables
Non-HBV-infected
Individuals
n=539, (%)
Self-limited
Infection
n=205, (%) Persistent infection
Total
n=496, (%)
CHC
n=89, (%)
IHC
n=101, (%)
CHB
n=108, (%)
LC
n=198, (%)
Alleles
G 898 (83.30) 341 (83.17) 812 (81.85) 155 (87.08) 173 (85.64) 180 (83.33) 304 (76.77)
A 180 (16.70) 69 (16.83) 180 (18.15) 23 (12.92) 29 (14.36) 36 (16.67) 92 (23.23)*
Genotypes
GG 376 (69.76) 142 (69.27) 337 (67.94) 69 (77.53) 74 (73.27) 75 (69.44) 119 (60.10){
AG 146 (27.09) 57 (27.80) 138 (27.82) 17 (19.10) 25 (24.75) 30 (27.78) 66 (33.33)
AA 17 (3.15) 6 (2.93) 21 (4.23) 3 (3.37) 2 (1.98) 3 (2.78) 13 (6.57){
CHB, chronic hepatitis B; CHC, chronic hepatitis B virus carrier; HBV, hepatitis B virus; IHC, inactive hepatitis B surface antigen carrier; LC, liver cirrhosis.
*Compared with the non-HBV-infected individuals, x
2=8.219 and P=0.004; and compared with the self-limited infection, x
2=5.167 and P=0.023.
{Compared with the non-HBV-infected individuals, x
2=6.124 and P=0.013.
{Compared with the non-HBV-infected individuals, x
2=5.594 and P=0.018.
doi:10.1371/journal.pone.0021997.t002
Table 3. Genotype distribution of rs430397 G.A in the fifth
intron of the GRP78 gene in HBV-infected individuals with
different HBeAg states.
Variables
Phase I
n=89, (%)
Phase II
n=104, (%)
Phase III
n=101, (%)
Phase IV
n=202, (%)
Age (mean 6 SD,
years)
34.869.5 42.4612.6 37.9610.3 46.5614.8
Gender
Female 38 (42.70) 41 (39.42) 44 (43.56) 70 (34.65)
Male 51 (57.30) 63 (60.58) 57 (56.44) 132 (65.35)
HBsAg state ++ + +
HBeAg state ++ 22
Clinical diagnosis CHC CHB or LC IHC CHB or LC
rs430397
Alleles
G 155 (87.08) 172 (82.69) 173 (85.64) 312 (77.23)
A 23 (12.92) 36 (17.31) 29 (14.36) 92 (22.77)*
Genotypes
GG 69 (77.53) 72 (69.23) 74 (73.27) 122 (60.40){
AG 17 (19.10) 28 (26.92) 25 (24.75) 68 (33.66){
AA 3 (3.37) 4 (3.85) 2 (1.98) 12 (5.94)
CHB, chronic hepatitis B; CHC, chronic hepatitis B virus carrier; HBeAg, hepatitis
B e antigen; HBV, hepatitis B virus; IHC, inactive hepatitis B surface antigen
carrier; LC, liver cirrhosis.
*Compared with the phase I group, x
2=7.562 and P=0.006; and compared with
the phase III group, x
2=5.969 and P=0.015.
{Compared with the phase I group, x
2=8.039 and P=0.005; and compared with
the phase III group, x
2=4.883 and P=0.027.
{Compared with the phase I group, x
2=7.131 and P=0.008.
doi:10.1371/journal.pone.0021997.t003
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CHB and LC. It was verified subsequently as we demonstrated a
statistical relationship of the rs430397 at allele and heterozygote
level with the progress of HBV infection.
Clinically, HBV infection does not invariably result in chronic
hepatitis since the host possesses the ability to eliminate the virus
spontaneously in most cases [32]. In acute infection, there is a
persistence of HBsAg, HBeAg, and HBV-DNA [33]. After the
acute hepatitis resolves, serum transaminases levels usually fall but
may remain abnormal. There may be a dectectable anti-HBc IgM
for the initial 6 months of infection that is later replaced by IgG.
Over time, there may be seroconversion as defined by a loss of
HBeAg and development of anti-HBe. Seroconversion is usually
preceded by a marked decrease in serum HBV-DNA. Serocon-
version may be associated with a flare in serum ALT levels but
these levels typically decrease and normalize after seroconversion
[34].
To decrease the bias of age and gender on the effect of
estimates, we conducted multivariable logistic regression analysis
and the association between rs430397 and the progression of HBV
infection remained significant. Among multiple parameters
evaluating liver function, ALB is quantitatively the most important
of several plasma proteins formed in the liver [35]. Accordingly,
measurement of total concentration of ALB is a useful test of
hepatic synthetic function. The relatively long half-life of ALB
makes the albumin level a better index of severity and prognosis in
patients with chronic liver disease such as LC [36]. And also, these
diseases are the common cause of impaired coagulation which was
reflected by prolonged PT [37]. In patients with HBV-related LC,
we found patients carrying AA genotype had relatively lower ALB
levels and higher PTs compared with those carrying GG genotype.
This fact further supports the potential association of rs430397
with the outcome of HBV infection.
Increasing evidence demonstrated that HBV infection is
associated with oxidative stress, which also may cause structural
Table 4. Relationship between rs430397 G.A distribution and liver functional profiles in patients with liver cirrhosis.
Demographic data and main liver function profiles
GG
n=119
AG
n=66
AA
n=13
Age (mean 6 SD, years) 42.2611.7 43.5610.2 45.1612.0
Gender (female/male) 49/70 21/45 4/9
HBeAg-positive cases (n, %) 50 (42.02) 21 (31.82) 4 (30.77)
HBV-DNA level (lg copies/mL) 4.1261.85 5.9662.33 6.3261.25
T-Bil (mmol/L) 192.46169.1 151.66124.9 170.66128.9
ALB (g/L) 27.166.7 24.965.8 23.666.9*
ALT (IU/L) 170.86145.9 145.36119.3 158.86135.3
AST (IU/L) 133.06101.6 139.8699.9 159.56127.8
GGT (IU/L) 92.0622.5 78.5630.1 71.4646.3
PT (seconds) 22.766.5 26.366.0 29.066.7{
SD, standard deviation; T-Bil, total bilirubin; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, c-glutamyltransferase; PT, prothrombin
time.
*Compared with the GG group, x
2=4.461 and P=0.029.
{Compared with the GG group, x
2=5.832 and P=0.016.
doi:10.1371/journal.pone.0021997.t004
Table 5. rs430397 G.A polymorphism and cirrhosis risk in
HBV patients.
Alleles/
Genotypes
Noncirrhosis
n=298, (%)
Cirrhosis
n=198, (%) OR (95%CI)* P*
G 508 (85.23) 304 (76.77) 1
A 88 (14.77) 92 (23.23) 1.75 (1.26–2.42) 0.001
GG 218 (73.15) 119 (60.10) 1
AG 72 (24.16) 66 (33.33) 1.68 (1.12–2.51) 0.011
AA 8 (2.68) 13 (6.57) 2.98 (1.20–7.39) 0.014
P-trend{ 0.005
*Pearson Chi-square test.
{Multivariable logistic regression analysis adjusted with age and gender.
doi:10.1371/journal.pone.0021997.t005
Table 6. Comparison between advanced and mild liver
cirrhosis patients according to Child-Pugh score.
Parameters A1 C+B1 P
Age (years, mean6SD) 41.8610.6 44.5611.9 0.559*
Gender
Female 23 (53.49) 51 (32.90)
Male 20 (46.51) 104 (67.10) 0.162{
HBeAg positive 20 (46.51) 55 (35.48) 0.187{
rs430397
Alleles
G 75 (87.21) 229 (73.87)
A 11 (12.79) 81 (26.13) 0.010{
Genotypes
GG 32 (74.42) 87 (56.13)
AG 11 (25.25) 55 (35.48) 0.115{
AA 0 (0.00) 13 (8.39) 0.032{
P-trend 0.021{
*Mann-Whitney U-test.
{Pearson Chi-square test.
{Multivariable logistic regression analysis adjusted with age and gender.
1Child-Pugh classification.
doi:10.1371/journal.pone.0021997.t006
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S proteins are retained in the endoplasmic reticulum (ER) and
subsequently induce ER stress, leading to the expression of ER
chaperone GRP78. Accumulation of GRP78 induces ER stress
signaling pathway, including unfolded protein response (UPR) and
ER overload response [40]. In addition, cells infected by viruses
are usually killed by a variety of reactive oxygen species (ROS),
which are produced by Kupffer and inflammatory cells [41].
Unfortunately, through these defense mechanisms, oxidative stress
may become inevitable and result in oxidative damage to DNA or
other macromolecules. Chronic inflammation caused by HBV
induced the release of free radicals, cytokines and chemokines
resulting in cell proliferation, DNA damage, fibrosis and
angiogenesis, and frequently associated with increased hepatocar-
cinogenesis risk [39]. Cirrhosis may also indicate pathological and
genetic changes throughout the liver leading to a field canceriza-
tion effect, which increases the risk of hepatocarcinogenesis.
GRP78 pathway is one of the most important responders to
disease-associated stress [42]. Therefore, rs430397 polymorphism
of GRP78 gene in the present study might be owing to, at least
partially, genetic instability induced by HBV-related cirrhosis.
Our study was limited by the small number of patients, but
there would be some concern over the ethics of enrolling further
large numbers of patients who were follow-up information on
patient survival outcomes. Taken together, the present investiga-
tion first revealed a contributing factor (rs430397 within GRP78
gene) to LC in persistent HBV carriers in Chinese Han population.
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